Patent 7862817 was granted and assigned to Genentech on January, 2011 by the United States Patent and Trademark Office.
The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies.